Letter to the EditorType 2 innate lymphoid cells in induced sputum from children with severe asthma
References (9)
- et al.
Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33
J Allergy Clin Immunol
(2015) - et al.
Innate lymphoid cells–a proposal for uniform nomenclature
Nat Rev Immunol
(2013) - et al.
GATA binding protein 3(+) group 2 innate lymphoid cells are present in cord blood and in higher proportions in male than in female neonates
J Allergy Clin Immunol
(2014) - et al.
Type 2 innate lymphoid cells—new members of the “type 2 franchise” that mediate allergic airway inflammation
Eur J Immunol
(2012)
Cited by (119)
Group 2 innate lymphoid cells in human asthma
2023, Allergology InternationalCitation Excerpt :Consistently, Jia et al. have shown that the percentages of peripheral blood IL-13-producing ILC2s are significantly higher in patients with uncontrolled asthma than in patients with well-controlled asthma or healthy subjects.59 Moreover, Nagakumar et al. have shown that the frequencies of ILC2s in sputum are increased in pediatric patients with severe therapy-resistant asthma compared to difficult asthma or disease controls.60 Interestingly, peripheral blood ILC2 counts and serum TSLP concentrations have been shown to be significantly higher in patients with eosinophilic granulomatosis with polyangiitis (EGPA), which is usually accompanied by severe asthma, than those with asthma.61
Roles of innate lymphoid cells (ILCs) in allergic diseases: The 10-year anniversary for ILC2s
2021, Journal of Allergy and Clinical ImmunologyCitation Excerpt :For example, circulating ILC2 frequencies did not differ among patients with well-controlled, partially controlled, or uncontrolled asthma.110 ILC2 frequencies were increased in sputum, but not in peripheral blood, of pediatric patients with severe asthma.114 Finally, no correlation was found between circulating ILC2s and eosinophils in nonallergic asthma.113
Macrophage metabolic reprogramming during chronic lung disease
2021, Mucosal ImmunologyDiagnosing, Monitoring and Treating Asthma
2021, Encyclopedia of Respiratory Medicine, Second Edition
Disclosure of potential conflict of interest: P. Nagakumar and S. Saglani have received research support from Asthma UK. L. Fleming has received consultancy fees from Chiesi and has received lecture fees from Novartis. C. M. Lloyd has received research support from the Wellcome Trust (grant). The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to the study.